Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
- Benboubker, Lotfi
- Dimopoulos, Meletios Athanassios
- Dispenzieri, Angela
- Catalano, John
- Belch, Andrew AR
- Cavo, Michele
- Pinto, Antonello
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar NJ
- Banos, Anne
- Tiab, Mourad
- Delforge, Michel
- Cavenagh, Jamie
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- de la Rubia, Javier
- Qiu, Lugui
- White, Darrell J
- Binder, Daniel
- Anderson, Kenneth Carl
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Van Oostendorp, Jason
- Jacques, Christian
- Ervin-Haynes, Annette
- Avet-Loiseau, Herve
- Hulin, Cyrille
- Facon, Thierry
- Meuleman, Nathalie
DOIAbstract
The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches.0info:eu-repo/semantics/publishe
Add to ORKG